CRSP crisprtx.com: Net Asset Value

This daily price chart for CRISPR Therapeutics AG (CRSP) reflects the price action of an asset whose value at 1.73 is largely independent of general economic cycles. The company's growth is driven by the launch of the first commercial sales of its gene therapy drug. As a leader in CRISPR/Cas9, CRISPR Therapeutics AG (CRSP) develops solutions for clinics and individuals with severe genetic disorders. Innovative DNA editing methods used to combat oncology and anemia are becoming a unique hope for patients.

For fundamental asset screening, it is critical to decouple market volatility from the actual net asset value of an enterprise. By analyzing the firm's book capitalization history, an investor can discern the difference between market hype and accounting assets, which for biotech pioneer CRISPR Therapeutics AG (CRSP) confirms financial stability during the commercialization of genome editing patents and the market launch of the innovative drug Casgevy.